|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Johnson_&_Johnson_Services,_Inc.
|
|
gptkbp:acquisition
|
gptkb:Johnson_&_Johnson
gptkb:2020
$6.5 billion
|
|
gptkbp:business_model
|
biotech innovation
|
|
gptkbp:ceo
|
Craig A. Wheeler
|
|
gptkbp:clinical_trial
|
Phase 3
biologics
|
|
gptkbp:collaborations
|
universities
biopharmaceutical companies
biotech industry
|
|
gptkbp:committee
|
experts
|
|
gptkbp:employees
|
approximately 200
|
|
gptkbp:financial_performance
|
publicly reported
|
|
gptkbp:focus
|
drug development
|
|
gptkbp:founded
|
gptkb:2001
|
|
gptkbp:founder
|
Craig A. Wheeler
|
|
gptkbp:goal
|
improve patient outcomes
|
|
gptkbp:headquarters
|
gptkb:Cambridge,_Massachusetts
|
|
gptkbp:healthcare
|
FDA approved
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Momenta Pharmaceuticals
|
|
gptkbp:investment
|
institutional investors
R& D
|
|
gptkbp:language_of_instruction
|
therapeutic candidates
drug candidates
|
|
gptkbp:leadership
|
scientific expertise
|
|
gptkbp:market
|
biopharmaceuticals
|
|
gptkbp:marketing_strategy
|
partnerships
|
|
gptkbp:partnership
|
gptkb:Sandoz
academic institutions
|
|
gptkbp:products
|
gptkb:M923
therapeutics
M230
M281
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
|
|
gptkbp:research
|
monoclonal antibodies
|
|
gptkbp:research_areas
|
gptkb:healthcare_organization
neurology
hematology
infectious diseases
immunology
inflammatory diseases
|
|
gptkbp:research_focus
|
rare diseases
autoimmune disorders
|
|
gptkbp:specialization
|
autoimmune diseases
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:symbol
|
MNTA
|
|
gptkbp:tactics
|
innovation
|
|
gptkbp:treatment
|
gptkb:M923
M230
M281
|
|
gptkbp:website
|
www.momentapharma.com
|